Release date: July 17, 2017
Expiration date: July 17, 2018
Estimated time to complete activity: 1.0 hour(s)
Robert Rahimi, MD, MSCR
Baylor University Medical Center
Department of Medicine
Texas A&M Health Science Center
College of Medicine
Liver Consultants of Texas
Baylor Charles A. Sammons Cancer Center
Cirrhosis is a chronic liver disease stage that results from a variety of causes of liver damage. Liver damage may induce secondary complications such as portal hypertension, esophageal variceal bleeding, spontaneous bacterial peritonitis, and hepatic encephalopathy (HE). HE is a potentially reversible state of impaired cognitive function or altered consciousness in patients with acute or chronic liver disease or portosystemic shunting. The buildup of ammonia in the blood causes brain swelling which leads to the clinical manifestations of HE. The level of neurologic and psychiatric impairment can vary from a subtly altered mental status to a deep coma. HE has been shown to have a substantial burden on patients, their families and caregivers, as well as healthcare utilization. Both the increasing number of patients with cirrhotic liver disease and HE secondary to cirrhosis as well as increasing healthcare costs require that healthcare providers re-evaluate current practice and make any necessary changes to the care of these patients to adapt to these ever-rising trends.
Hospital Medicine Summit (HMS) is an innovative, multi-topic educational initiative designed specifically for hospital-based healthcare providers (hospitalists, internal medicine physicians, physician assistants, nurse practitioners, pharmacists, and nurses). With significant changes occurring in the healthcare system, there is an increased demand on hospital-based healthcare providers to provide care that impacts patients not only in the acute setting, but as they transition back into the community and are managed in the chronic-care healthcare system.
This educational initiative has been designed for hospital-based healthcare providers, including physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists.
Upon completion of this educational activity, participants should be able to:
- Describe the burden and need to prevent recurrence and rehospitalizations for overt HE
- Evaluate the efficacy and safety of available and emerging agents for secondary prophylaxis of HE
- Utilize management plans that include long-term treatment strategies to care for patients with HE
Directions to Learner
There are no fees for participating and receiving CME/CE credit for this activity. During the period of July 17, 2017 through July 17, 2018, participants must:
- Read the learning objectives and faculty disclosures
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.100 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number: 0530-9999-17-139-H01-P)
This educational activity for 1.0 contact hours is provided by Global Education Group.
Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Disclosure of Conflicts of Interest
Integrity Continuing Education, Inc. and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education and Global Education Group for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Integrity Continuing Education and Global Education Group are committed to providing learners with high-quality CME/CE activities and related materials that promote improvement or quality in healthcare and not a specific proprietary business interest or a commercial interest.
The following faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Robert Rahimi, MD
Research: Ocera Therapeutics
The following planners and managers, Andrea Funk, Laura Gilsdorf, Amanda Glazer, PhD, Ashley Marostica, RN, MSN, and Patima Tanapat, PhD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integrity Continuing Education, Global Education Group, and Salix Pharmaceuticals, Inc., a division of Valeant Pharmaceuticals North America LLC, do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Global Education Group, and Salix Pharmaceuticals, Inc., a division of Valeant Pharmaceuticals North America LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)
Minimum System Requirements
Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10
Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Flash Player 10
Use of Internet Explorer browser is not recommended.
Click here for more information on minimum system requirements.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.Provider Statement
This CME activity is provided by Integrity Continuing Education.
This CEU/CNE activity is jointly provided by Global Education Group and Integrity Continuing Education.
Supported by an educational grant from Salix Pharmaceuticals, Inc., a division of Valeant Pharmaceuticals North America LLC.
- Hospital-based healthcare providers
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.